


Incite Health, Inc. Announces the Launch of a New Paradigm in Lyme Disease Testing

DOYLESTOWN, PA, UNITED STATES, August 1, 2023 /EINPresswire.com/ -- Incite Health, Inc., a CLIA-certified, CAP-accredited, high complexity clinical laboratory specializing in immune system testing, announces the launch of a new paradigm in [Lyme Disease](#) testing, the ZEUS Scientific MTTT-2™ ELISA system.



The Zeus Modified Two-Tiered Testing (MTTT-2) ELISA system is an FDA-cleared assay that has been shown to reduce the number of missed clinically positive samples compared with the Standard Two-Tiered Testing (STTT) algorithm that relies on a second tier immunoblot. Incite Health is offering the MTTT-2 Lyme testing algorithm, providing the highest levels of sensitivity and specificity available in Lyme antibody testing on the market today. The MTTT-2 uses a VlsE1/pepC10 polyvalent ELISA as the initial screen, followed by separate second tier IgG and IgM confirmatory ELISAs; this delivers the highest sensitivity for early detection of Lyme without compromising specificity.

Recently, the CDC updated their recommendation to state that serologic assays using a second ELISA test are an acceptable alternative to assays that use an immunoblot as a second test.

Lyme Disease is caused by the bacterium *Borrelia burgdorferi* and is transmitted to humans through the bite of an infected blacklegged tick. Lyme disease is the most reported vector-borne illness in the United States, and cases have been reported in all 50 states. The symptoms of Lyme Disease are highly variable and similar to those of several other diseases. The most common symptoms of Lyme Disease are fever, headache, fatigue, joint pain and reduced mobility, muscle pain, along with cognitive problems.

About Incite Health:

Incite Health is at the forefront of healthcare innovation with the development of clinically actionable Health & Wellness screening assays, leveraging its proficiency and expertise in the

immune system. Incite Health recognizes the powerful health benefits of monitoring an individual's cellular health profile through the tracking of key biomarkers of the immune system and offers a portfolio of IVD cleared assays for clinicians and medical professionals.

To learn more, please visit www.incitehealth.com

Contact:

Media/Investors please contact:

Connie Scotese

Director, Business Development

Incite Health, Inc.

cscotese@incitehealth.com 610-454-9828

Connie Scotese

Incite Health

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/646914773>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.